ICG plc, through its Life Sciences team, has co-led an oversubscribed $76 million Series B equity financing round for Mediar Therapeutics, Inc., a clinical-stage biotechnology company focused on first-in-class therapies for fibrotic diseases. The round was co-led with Amplitude Ventures and included participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities, as well as existing Series A investors. The proceeds will support the continued clinical advancement of Mediar's portfolio of anti-fibrotic therapeutics, including therapies targeting systemic sclerosis, idiopathic pulmonary fibrosis, and fibrosis associated with chronic kidney disease. As a part of the transaction, Dr Allan Marchington, Head of ICG Life Sciences, will join Mediar’s board of directors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICG plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.